

Garlic-Derived Organic Polysulfides and Myocardial Protection^{1–3}

Jessica M Bradley, Chelsea L Organ, and David J Lefer*

Department of Pharmacology and Experimental Therapeutics and Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA

Abstract

For centuries, garlic has been shown to exert substantial medicinal effects and is considered to be one of the best disease-preventative foods. Diet is important in the maintenance of health and prevention of many diseases including cardiovascular disease (CVD). Preclinical and clinical evidence has shown that garlic reduces risks associated with CVD by lowering cholesterol, inhibiting platelet aggregation, and lowering blood pressure. In recent years, emerging evidence has shown that hydrogen sulfide (H₂S) has cardioprotective and cytoprotective properties. The active metabolite in garlic, allicin, is readily degraded into organic diallyl polysulfides that are potent H₂S donors in the presence of thiols. Preclinical studies have shown that enhancement of endogenous H₂S has an impact on vascular reactivity. In CVD models, the administration of H₂S prevents myocardial injury and dysfunction. It is hypothesized that these beneficial effects of garlic may be mediated by H₂S-dependent mechanisms. This review evaluates the current knowledge concerning the cardioprotective effects of garlic-derived diallyl polysulfides. *J Nutr* 2016;146(Suppl):403S–9S.

Keywords: hydrogen sulfide, nitric oxide, acute myocardial infarction, heart failure, cardioprotection

Introduction

Diet plays a critical role in the management and prevention of various diseases. Studies have shown that the Mediterranean diet (rich in fruits and vegetables) reduces the incidence of cardiovascular events (1–3). For centuries, garlic (*Allium sativum*) has been studied for its beneficial health effects and is considered one of the best disease-preventative foods. Preclinical and clinical studies have shown that daily garlic supplementation reduces cholesterol, inhibits platelet aggregation, and reduces blood pressure. Garlic has also been shown to improve vascular function; however, more research is needed to fully conclude that garlic can improve overall cardiovascular health (4). The impact of garlic on heart health is primarily due to the active metabolite allicin and its breakdown into organic polysulfides. Although the direct mechanism of action requires further elucidation, our group and others have hypothesized that hydrogen sulfide (H₂S)⁴ may have a critical role in garlic-induced cardioprotection (5–8). A primary mechanism by which garlic augments H₂S bioavailability is via the transformation of garlic-derived polysulfides. Organic sulfides contained in high concentrations in garlic interact readily with thiol groups or thiol-containing compounds (i.e., glutathione) found in biological systems to generate free H₂S.

Cardiovascular Disease

Cardiovascular disease (CVD) is a multifactorial disease resulting from disorders of the heart and circulation and is the

number one cause of death worldwide (9). The risk factors associated with CVD are primarily lifestyle-related and include the following: unhealthy diet, tobacco use, excessive alcohol consumption, or lack of physical activity leading to increases in blood pressure, blood lipids, and obesity (10). Improving diet and lifestyle are key preemptive measures in reducing the risk of developing CVD (10). Although there are promising clinical studies that suggest adding garlic to a daily dietary regimen may help reduce risk factors associated with CVD, the hypothesis that garlic will decrease the incidence of heart attack or stroke requires further examination (11).

Garlic Preparation and Intake

The interests in the potential health effects of garlic can be traced back to the beginnings of civilization. The earliest records from ancient Egypt indicate garlic as a regular source of nutrients in daily diet (12). A recurring theme throughout early history was the addition of garlic to the daily diet of the working class to increase strength, improve work capacity, and increase satiety (11, 13). Ancient medical texts from Egypt, Greece, China, India, and Rome all prescribe garlic to aid with respiratory and digestive disorders, to reduce infections, and to treat heart disease (12). In combination with being a food preservative and flavor enhancer, garlic has potent therapeutic effects. These beneficial effects of garlic on cardiovascular health are still being investigated today. New evidence has emerged suggesting that the cardioprotective effects of garlic are largely determined by the method of preparation (11, 14, 15).

Raw garlic. Raw intact garlic bulbs, although composed of 65% water, contain high amounts of γ -glutamylcysteine, which can undergo hydrolysis or oxidation to form inactive cysteine sulfoxides, alliin (14). During storage in cool temperatures, alliin naturally accumulates (up to ~1%) in the garlic bulbs (14). Destruction of the intact garlic bulb by crushing, cutting, or ingesting it results in the activation of the allinase enzyme, promoting the conversion of alliin to the active metabolite allicin (diallyl thiosulfanate) (14). Allicin is an extremely unstable and odorless compound that readily breaks down into the organic diallyl polysulfides diallyl sulfide (DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS) as well as ajoene (11, 14, 15).

Garlic powder and oil. Garlic powder, a dehydrated, pulverized garlic clove, has a composition identical to raw garlic; therefore, it is capable of producing the biologically active allicin and its metabolites, the organic polysulfides DAS, DADS, and DATS (11). Garlic oil is formed through steamed distillation of the whole garlic clove in organic solvents. Although allicin is not contained in the extracted oil fragment, both DADS and DATS are readily available (14).

Aged garlic extract. Aged garlic extract (AGE) is prepared by storing raw sliced garlic in 15–20% ethanol for 20 mo in a stainless steel tank. The extract is then filtered and concentrated at low

temperatures. AGE is sold in either a dry or liquid form, with the liquid form containing 10% ethanol. The aging process increases the activity of potent antioxidants, including S-allylcysteine and S-allylmercaptocysteine, giving AGE a greater antioxidant capacity than fresh garlic and garlic supplements (16). Moreover, the aging process modifies the harsh and irritating components found in raw garlic. Unlike raw garlic, AGE does not contain allicin, yet it does contain the diallyl polysulfides DAS and DADS (16).

Daily intake. Although there is no standard intake of raw garlic, recent clinical studies have shown that the effective daily dosage of garlic powder ranges from 150 to 2400 mg. Aged garlic intakes range from 0.25 to 7.2 g/d.

Atherosclerosis

Atherosclerosis is a complex disease caused by the thickening of arterial walls, resulting in a reduction in blood flow. Several factors, including high serum lipids, excessive inflammation, and coronary artery calcification, can promote the development of plaque formation or vessel remodeling, increasing the risk of atherosclerosis. Garlic has been shown to have many antiatherosclerotic properties.

Preclinical studies. Elevated plasma cholesterol, specifically LDL cholesterol, is recognized as the primary cause of atherosclerosis. Garlic's antihyperlipidemic effect has been studied for some time. Several investigators showed that oral administration of allicin garlic powder (5–50 mg/kg body weight) or raw garlic extract (3–300 mg/kg body weight) significantly reduced total plasma cholesterol, LDL cholesterol, and TGs in response to high-cholesterol diets in rodents (17–19). It is suggested that allicin and raw garlic may be involved in cholesterol modification by reducing circulating concentrations of oxidized LDL and impairing lipid peroxidation (18, 19). In addition, allicin significantly lowered hepatic cholesterol storage in Institute for Cancer Research mice fed a high-cholesterol diet, demonstrating the ability of allicin to prevent fatty liver by alleviating liver stress in response to hypercholesterolemia (19). Similarly, the administration of the garlic-derived polysulfide DADS analog was also effective in lowering total lipid concentrations in hypercholesterolemic rats (17).

In rat hepatocyte culture, water-soluble garlic extracts reduced cholesterol biosynthesis and exported into the media by 20–30% (20). Moreover, low concentrations of garlic extracts (20) or DADS analog (17) reduced β -hydroxy- β -methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate and determines the rate of cholesterol synthesis in the liver. Higher concentrations of garlic extracts inhibit other key enzymes in the cholesterol biosynthesis pathway such as FA synthase, cholesterol 7 α -hydroxylase, and cholesterol acyltransferase (20). Gebhardt (20) concluded that different garlic-derived organic polysulfide compounds interfere at various points of the cholesterol biosynthesis pathway, eliciting inhibition at multiple points in this metabolic pathway in response to garlic consumption. Together, these in vitro studies showed the cellular mechanisms responsible for garlic's effect on cholesterol and TG biosynthesis; however, further investigation is needed to determine whether these garlic-induced mechanisms transition to in vivo models.

In the past decade, studies demonstrated that AGE may have an integral role in inhibiting LDL cholesterol uptake. During the

¹ Published in a supplement to *The Journal of Nutrition*. Presented at the conference "2014 International Garlic Symposium: Role of Garlic in Cardiovascular Disease Prevention, Metabolic Syndrome, and Immunology," held 4–6 March 2014 at St. Regis Monarch Beach Resort in Dana Point, CA. This supplement is dedicated to our colleague and friend John A. Milner. His dedication to good science and his voice for nutrition are remembered and sorely missed. The symposium was sponsored by the University of California, Los Angeles School of Medicine and the University of Florida and co-sponsored by the American Botanical Council; the American Herbal Products Association; the ASN; the Japanese Society for Food Factors; the Japan Society for Bioscience, Biotechnology, and Agrochemistry; the Japan Society of Nutrition and Food Science; and the Natural Products Association. The symposium was supported by Agencias Motta S.A.; Bionam; Eco-Nutraceuticos; Healthy U 2000 Ltd.; Magna; Mannavita Bvba; MaxiPharma; Medica Nord A.S.; Nature's Farm Pte. Ltd.; Nature Valley W.L.L.; Organic Health Ltd.; Oy Valoravinto Ab; Purity Life Health Products L.P.; PT Nutriprima Jayasakti; Vitaco Health Ltd.; Vitae Natural Nutrition; Sanofi Consumer Health Care; Wakunaga Pharmaceutical Co., Ltd.; and Wakunaga of America Co., Ltd. The Chair of the conference and Scientific Program Coordinator for the supplement publication was Matthew J. Budoff, Harbor-UCLA Medical Center, Torrance, CA. Scientific Program Coordinator disclosures: MJ Budoff has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Chair of the conference. Vice-Chair and Supplement Coordinator for the supplement publication was Susan S. Percival, University of Florida, Gainesville, FL. Supplement Coordinator disclosures: SS Percival has been awarded research grants from Wakunaga of America Co., Ltd., and received an honorarium for serving as Vice-Chair of the conference. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of *The Journal of Nutrition*.

² Supported by grants from the National Heart, Lung, and Blood Institute (1R01 HL092141, 1R01 HL093579, 1U24 HL 094373, and 1P20 HL113452; to DJL) and by the Louisiana State University Health Foundation in New Orleans.

³ Author disclosures: JM Bradley, CL Organ, and DJ Lefer, no conflicts of interest.

⁴ Abbreviations used: AGE, aged garlic extract; CAC, coronary artery calcification; CAD, coronary artery disease; CBS, cystathionine β -synthase; CRP, C-reactive protein; CSE, cystathionine γ -lyase; CVD, cardiovascular disease; DADS, diallyl disulfide; DAS, diallyl sulfide; DATS, diallyl trisulfide; eNOS, endothelial nitric oxide synthase; GPIIb/IIIa, glycoprotein IIb/IIIa; HMG-CoA, β -hydroxy- β -methylglutaryl coenzyme A; H₂S, hydrogen sulfide; TAC, transverse aortic constriction; 3-MST, 3-mercaptopyruvate sulfurtransferase.

*To whom correspondence should be addressed. E-mail: dlefe1@lsuhsc.edu.

TABLE 1 Clinical studies of dietary garlic on cardiovascular risks¹

Study design	Intervention/control groups	Sample size	Type of garlic preparation: dosage, duration	Effects of garlic intervention	Reference
Randomized, observer-blinded, crossover, placebo controlled	Raw garlic/placebo	18 Healthy volunteers	Raw garlic: 4.2 g	No significant change	(23)
Randomized, double-blinded, placebo controlled	Garlic oil/placebo	27 Healthy male long-distance runners	Garlic oil: 12.3 mg/d, t.i.d., 16 wk	LDL-C: 0.0019-g/mL reduction in TGs: 0.20-mmol/L reduction	(24)
Randomized, double-blinded, placebo controlled	Garlic oil/garlic powder/placebo	51 Normal subjects	Garlic oil: 8.2 mg/d b.i.d.; garlic powder: 7.8 mg/d b.i.d., 3 mo	Males: No significant change; females: HDL-C increase and total cholesterol reduction	(25)
Randomized, single-blinded, placebo controlled	Garlic powder tablets/anethum/placebo	150 Hyperlipidemic patients	Enteric-coated garlic powered tablets: 400 mg garlic + 1 mg allicin b.i.d., 6 wk	Total cholesterol: 12.1% reduction; LDL-C: 17.3% reduction	(26)
Randomized, double-blinded, placebo controlled	TR garlic tablets, low dose/TR garlic tablets, high dose/garlic tablets/placebo	84 Newly diagnosed mildly to moderately hypertensive patients	TR garlic tablets (Allicor): 600 or 2400 mg b.i.d.; Kwai: 900 mg daily, 8 wk	Antihypertensive Allicor: 7 mm Hg SBP decrease and 3.8 mm Hg DBP decrease; Kwai: 7 mm Hg SBP decrease	(27)
Randomized, double-blinded, placebo controlled	TR garlic tablets/placebo	51 CAD patients	TR garlic tablets: 150 mg/d b.i.d., 12 wk	LDL-C reduction: males, 32.9 mg/dL; females, 27.3 mg/dL	(28)
Randomized, double-blinded, placebo controlled	AGE + S-allyl cysteine/placebo	50 Patients with uncontrollable hypertension	AGE: 960 mg b.i.d., 12 wk	Antihypertensive: 10.2 mm Hg SBP decrease	(29)
Randomized, double-blinded, placebo controlled	AGE + vitamin B-12 + folic acid + vitamin B-6 + L-arginine/placebo	65 Intermediate CAD risk patients, CAC >30	AGE: 250 mg, 1 y	CAC progression: 29% reduction, LDL-C: 13.6% reduction, anti-inflammatory markers: 41% mean annual change	(30)
Randomized, double-blinded, placebo controlled	AGE/placebo	79 Patients with uncontrollable hypertension	AGE: 240/480/960 mg b.i.d., 12 wk	Antihypertensive: 11.8 mm Hg SBP decrease	(31)
Randomized, double-blinded, crossover	AGE/placebo	34 Normal healthy adults	AGE: 2.4–7.2 g/d t.i.d., 44 wk	Antiplatelet aggregation and adhesion	(32)
Randomized, double-blinded, placebo controlled	AGE + Co Q10/placebo	65 Intermediate CVD risk firefighters	AGE: 1200 mg, 1 y	CAC progression: 3.99% reduction anti-inflammatory; 7.67% decreased CRP	(33)
Randomized, double-blinded, placebo controlled	AGE + Co Q10/placebo	65 Asymptomatic firefighters with CAC >20%	AGE: 300 mg, 1 y	Improved vascular reactivity: 1.2 m/s decreased PWV anti-inflammatory; 1.31 g/L decreased CRP	(34)
Randomized	AGE + vitamin B-12 + folic acid + vitamin B-6 + L-arginine/placebo	65 Asymptomatic patients with CAC >30%	AGE: 250 mg, 1 y	CAC progression: 65% reduction	(35)
Randomized, double-blinded, placebo controlled	AGE/placebo	19 Patients taking statin therapy	AGE: 4 mL, 1 y	CAC progression: 7.5% reduction	(36)

¹ AGE, aged garlic extract; b.i.d., twice daily; CAC, coronary artery calcification; CAD, coronary artery disease; Co Q10, coenzyme Q10; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; PWV, pulse-wave velocity; SBP, systolic blood pressure; t.i.d., three times daily; TR, time-released.

development of atherosclerotic lesions, increases in expression of the CD36 cholesterol scavenger receptor and macrophage differentiation play a critical role in oxidized LDL uptake and foam cell formation (21, 22). Using human monocyte/macrophages (THP-1 cells and primary human monocytes) incubated with homocysteine, AGE suppressed CD36 expression (21, 22), inhibited oxidized LDL uptake (22), and prevented macrophage differentiation (21). Moreover, Morihara et al. (21) revealed that suppression of CD36 by AGE was through the inhibition of PPAR- γ , which is the key regulator of oxidized LDL uptake.

Clinical studies. Since 2000, 11 clinical studies have examined garlic's effects on atherosclerotic risk factors, as outlined in Table 1. All were randomized, double-blind, placebo-controlled studies that used either garlic powder or AGE. Three of these trials examined garlic's lipid-lowering effects. Hyperlipidemic patients (26) and patients with coronary artery disease (CAD) (28, 30) showed a reduction in total cholesterol, LDL cholesterol, and TGs in response to daily garlic therapy. Similar findings were observed in a study of healthy male long-distance runners (25). Zhang et al. (24) found that although there was no effect of garlic on cholesterol in normal male subjects, garlic did lower total cholesterol and increase HDL cholesterol in female subjects, suggesting a potential gender effect.

C-reactive protein (CRP) is an important marker of inflammation and a cardiovascular risk factor (37, 38). During atherosclerosis, CRP deposits into the arterial walls, promoting the upregulation of adhesion molecule expression on endothelial cells (37). CRP also plays a critical role in the formation of foam cells by opsonizing lipid particles in the arterial walls (39). In addition, CRP activates complement, thus linking lipid deposition to the induction of atherosclerosis (39). In 2 clinical trials involving asymptomatic (33) and intermediate-risk (35) patients with CAD, CRP was reduced after daily garlic therapy using AGE (1200- and 300-mg doses).

Calcification is an early factor of plaque formation, which begins at the onset of the fatty streak and progresses during the development of atherosclerosis (34). Coronary artery calcification (CAC) is an excellent marker of coronary atherosclerotic burden (36). The examination of CAC progression in asymptomatic and intermediate-risk patients with CAD revealed that daily garlic intake attenuated CAC progression.

The antiatherosclerotic properties of garlic have not been without inconsistencies. Both preclinical and clinical studies have shown that garlic has no significant impact on plasma cholesterol concentrations; however, it is hypothesized that the composition and preparation of the garlic, as well as the quantity of the sulfur components in the garlic, led to these inconsistent results.

Platelet Aggregation

Platelet aggregation is a risk factor for the development of CAD. In the injured vessel, the damaged endothelium leads to exposure of collagen, laminin, and von Willebrand factor, causing platelets to adhere and aggregate. Preclinical and clinical studies showed that garlic and its various preparations have the ability to inhibit platelet aggregation.

Preclinical studies. There are limited preclinical studies that have examined the mechanisms of how garlic inhibits platelet activation. Studies reported that garlic, specifically AGE, impairs various points of the aggregation cascade. Substances that stimulate platelet aggregation, such as ADP, act to initiate

the mobilization of calcium stores, inducing aggregation, shape change, and secretion (40). AGE, specifically its water-soluble components (40), and DATS (41) suppress calcium mobilization in vitro. Allison et al. (42, 43) showed that AGE increases cAMP and promotes calcium reuptake into the plasma tubular system by stimulating activation of the ATP-dependent calcium pumps.

When ADP induces platelet activation, there is a conformational change within the glycoprotein IIb/IIIa (GPIIb/IIIa) fibrinogen receptor—a process known as “inside out” signaling (43). This process increases the affinity of fibrinogen to GPIIb/IIIa and, upon binding, will stimulate a shape change to induce platelet aggregation. AGE inhibits the binding of fibrinogen to the GPIIb/IIIa receptor, causing the disaggregation of platelets (43). Garlic also stimulates other regulators of platelet aggregation, such as enhancing NO bioavailability (44) and reducing thromboxane (45).

Clinical studies. As shown in Table 1, 2 clinical studies showed that garlic inhibited platelet activation in normal healthy individuals following a daily regimen of AGE. In a randomized, double-blind crossover study, Steiner and Li (32) observed an increase in the threshold level of ADP-induced platelet aggregation at the highest amount of supplementation (7.2 g/d). In addition, AGE reduced adherence to fibrinogen at both low and higher supplementations, whereas adherence to the von Willebrand factor was reduced only at higher amounts of AGE. It was also determined that AGE mediates a dose-dependent reduction in adherence to collagen at low shear-stress levels. It was concluded from these findings that AGE exerts selective inhibition on platelet adherence and aggregation (32).

Contradictory to those findings, Scharbert et al. (23) observed no significant inhibition of platelet aggregation after 1 wk of raw garlic consumption (~1–2 garlic cloves). The major discrepancy between these studies is the use of raw garlic compared with processed garlic such as AGE or garlic powders. Processed garlic has been thought to increase the potency and bioavailability of the organosulfides, allowing them to be more readily active in the circulation than raw garlic (46).

Blood Pressure and Vascular Reactivity

Hypertension affects 1 in 4 adults and is attributed to ~40% of cardiovascular-related deaths (31). In both clinical (47, 48) and preclinical (49, 50) models, dietary garlic intake has been shown to reduce blood pressure.

Preclinical studies. Preclinical studies concluded that dietary garlic has substantial antihypertensive properties. Raw garlic (50, 51) and AGE (50) reduced systolic blood pressure in spontaneously hypertensive rats. Harauma and Moriguchi (50) reported that AGE improves artery extensibility and prevents stiffness, suggesting an additional direct effect on the vascular wall to improve vascular compliance. Similar antihypertensive results were reported in rats fed a high-cholesterol diet when administered garlic powder daily (49).

In a rat 2-kidney, 1-clip model of hypertension, daily garlic therapy attenuated the increase in blood pressure by increasing NO bioavailability (52). Mohamadi et al. (53) reported that NO plays a critical role in lowering systolic blood pressure in response to daily garlic and AGE therapy in spontaneously hypertensive rats. NO has an important role in vascular function, promoting the relaxation or suppression of contraction in the blood vessel, helping to regulate blood pressure. Raw garlic and AGE not only improved vascular reactivity (18, 54) and attenuated endothelial dysfunction (54), but several investigators

have reported that both raw garlic and AGE increase NO synthase activity and NO production (44, 55, 56). A study by Benavides et al. (15) concluded that garlic-derived polysulfide initiation of H₂S production mediates vasoreactivity. Aortic rings isolated from Sprague-Dawley rats showed a dose-dependent concomitant vasorelaxation and H₂S production in response to garlic (1 g/L) administration (15). Exogenous and endogenous H₂S activates ATP-sensitive K⁺ channels (57) in vascular smooth muscle, resulting in hyperpolarization of the cell membrane, inactivating the voltage-dependent L-type Ca²⁺ channel, and resulting in relaxation and dilation of the vessel.

Clinical studies. Garlic supplements have been shown to exert an effect on reducing blood pressure in hypertensive patients (58). AGE significantly reduced systolic blood pressure in patients with uncontrolled hypertension in as little as 4 wk after daily administration (29, 31). The investigation of the time-released garlic tablet Allicor (INAT-Farma, Moscow, Russia) compared with the regular garlic tablet Kwai (Lichtwer Pharma GmbH, West Berlin, Germany) revealed that both lowered systolic blood pressure in mild to moderate hypertension; however, only Allicor was capable of reducing diastolic blood pressure (27). Sobenin et al. (27) concluded that the time-released preparation of Allicor helps to sustain the bioactive components in the circulation. Allicor's biological effect lasts for 12–16 h after administration of a single dose (27). One clinical study examined the effect of AGE on vascular function. Asymptomatic fire fighters with high occupational stress who were enrolled in a daily AGE regimen for 1 y showed improved vascular elasticity and endothelial function (35).

Potential Mechanism of Garlic-Induced Cardioprotection

Although there is an abundant amount of evidence supporting the link between garlic and cardioprotection, the precise mechanism or mechanisms by which garlic prevents CVDs remains largely unknown. Many speculate that the inconsistent findings in both preclinical and clinical studies are due to the preparation of the garlic and availability of the bioactive components in the circulating blood. Furthermore, it is speculated that garlic-derived polysulfides play a critical role in cardioprotection. Benavides et al. (15) showed that garlic-derived polysulfides such as DATS and DADS are H₂S donors in the presence of thiols and thiol-containing compounds (i.e., glutathione), independent of the H₂S-forming enzymes cystathionine γ -lyase (CSE), cystathionine β -synthase (CBS), and 3-mercaptopyruvate sulfurtransferase (3-MST). H₂S, much like NO, is an endogenously produced gaseous signaling molecule that plays a critical role in many physiologic processes and has been shown to exert cytoprotective actions in various models of CVD and cardiovascular injury (5–8).

When compared with traditional, rapidly acting, direct H₂S donors (i.e., sodium sulfide or sodium hydrosulfide), garlic-derived DATS increases H₂S concentrations gradually over an extended period of time and augments endogenous concentrations (circulating and tissue) of H₂S after myocardial ischemia/reperfusion (59). Predmore et al. (59) showed that DATS therapy at the time of reperfusion either by intravenous or intraperitoneal routes resulted in significant reductions in myocardial injury, as observed by reduced areas of infarction and decreased circulating concentrations of cardiac troponin I, a marker of cardiac injury. Using mice genetically deficient in the H₂S-producing enzyme CSE, King et al. (60) showed that the




FIGURE 1 Garlic-derived polysulfides promote cardioprotection through H₂S and NO signaling. This schematic illustrates the hypothesis that the garlic-derived diallyl polysulfides (i.e., DAS, DADS, and DATS) are potent H₂S donors that increase phosphorylation at the eNOS active site Ser¹¹⁷⁷, enhancing NO bioavailability and inducing cardioprotective mechanisms. DADS, diallyl disulfide; DAS, diallyl sulfide; DATS, diallyl trisulfide; eNOS, endothelial nitric oxide synthase; H₂S, hydrogen sulfide; RSNO, nitrosothiols.

administration of DATS at the time of reperfusion restored H₂S concentrations and reduced infarction size.

Raw garlic, garlic oil, and garlic-derived polysulfides, all of which have H₂S-generating capability, have been shown to have an impact on cardiac structure and function (54, 61, 62). Raw garlic, which contains the active metabolite allicin, significantly attenuated right ventricular pressure and hypertrophy in a rat model of pulmonary hypertension and heart failure (54). Similarly, garlic oil containing the polysulfides DATS and DADS reduced the pathologic cardiac hypertrophy and improved contractile function in response to diabetes-induced cardiomyopathy (61). Garlic-derived DATS promoted similar cardioprotective results in a murine transverse aortic constriction (TAC) model of heart failure by attenuating TAC-induced left ventricle dilation and dysfunction (62). Furthermore, Polhemus et al. (62) found that DATS therapy mitigates the development of perivascular and intermuscular fibrosis.

Emerging evidence suggests that H₂S-mediated cardioprotection may be mediated via cross-talk with NO and is dependent on NO signaling (7, 59, 62–65). The administration of NO donors enhanced H₂S-producing enzymes CBS (66, 67) and CSE (68), promoting vessel relaxation. The vasorelaxant effect mediated by NO donors in rat thoracic aorta *ex vivo* was heightened with the administration of H₂S (69). Moreover, H₂S enhanced endothelial NO synthase (eNOS) activity and significantly increased NO bioavailability (70), thereby improving vascular function. Nie et al. (71) showed that, after coronary injury, intervention with stents coated with DATS increased

expression of eNOS and NO production, resulting in endothelialization and improved vascular function.

NO synthesis in the surrounding tissue is mediated via eNOS signaling of guanylyl cyclase to form the second-messenger system cyclic guanosine 5'-monophosphate. Multisite phosphorylation, specifically at Ser¹¹⁷⁷ or Thr⁴⁹⁵, regulate eNOS activity, ultimately enhancing or inhibiting NO production, respectively (72–74). In the presence of oxidized LDL, DADS and DATS restore eNOS function by phosphorylating the eNOS^{Ser1177}, resulting in increased concentrations of NO metabolites nitrite, nitrate, and total nitrosothiols (75). In murine models of heart failure, the administration of DATS at the time of reperfusion (59) or 24 h after TAC (62) resulted in significant upregulation of phosphorylated eNOS^{Ser1177} and heightened NO bioavailability. A potential avenue of exploration, as shown in **Figure 1**, would be to examine the effects of garlic's cardioprotective effects through polysulfide-derived H₂S activation of eNOS, resulting in increased NO bioavailability.

In conclusion, the beneficial health effects of garlic on cardiovascular health are dependent on multiple mechanisms. Furthermore, the mechanisms of action may be mediated by the active components in garlic. The breakdown of allicin into the organic polysulfides and subsequent interactions with thiol groups result in the generation of H₂S. Given the recent appreciation of the cardioprotective actions of H₂S in preclinical studies, it is possible that the beneficial effects of dietary garlic on CVD prevention and regression may be mediated in part by H₂S. Moreover, cross-talk between H₂S and NO signaling may further elucidate the protective effect that garlic has on vascular reactivity, vessel growth, and preservation of cardiovascular function. Further experimental and clinical studies are required to more clearly understand the protective effects of garlic and garlic-derived compounds on cardiovascular health.

Acknowledgments

JMB and CLO carried out the literature search and compilation of the reference articles; JMB and DJL prepared the figure, table, manuscript structure, and outline; and JMB, CLO, and DJL wrote the manuscript. All authors read and approved the final version of this manuscript.

References

- Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013;368:1279–90.
- de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;99:779–85.
- Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. *Lancet* 2002;360:1455–61.
- Qidwai W, Ashfaq T. Role of garlic usage in cardiovascular disease prevention: an evidence-based approach. *Evid Based Complement Alternat Med* 2013;125649:1–9.
- Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc Natl Acad Sci USA* 2007;104:15560–5.
- Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. *Circulation* 2010;122:11–9.
- Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G Sr., Gojon G Jr., et al. H(2)S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. *Circulation* 2013;127:1116–27.
- Polhemus DJ, Calvert JW, Butler J, Lefer DJ. The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure. *Scientifica* 2014;768607:1–8.
- Murphy SL, Xu J, Kochanek MA. Deaths: final data for 2012. *Natl Vital Stat Rep* 2015;61:1–118.
- Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, et al. American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation* 2006;114:82–96.
- Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. *Nutr J* 2002;1:1–4.
- Rivlin RS. Historical perspective on the use of garlic. *J Nutr* 2001;131(Suppl):951S–4S.
- Petrovska BB, Cekovska S. Extracts from the history and medical properties of garlic. *Pharmacogn Rev* 2010;4(7):106–10.
- Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. Intake of garlic and its bioactive components. *J Nutr* 2001;131(Suppl):955S–62S.
- Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE, Kraus DW. Hydrogen sulfide mediates the vasoactivity of garlic. *Proc Natl Acad Sci USA* 2007;104:17977–82.
- Borek C. Antioxidant health effects of aged garlic extract. *J Nutr* 2001;131(Suppl):1010S–5S.
- Rai SK, Sharma M, Tiwari M. Inhibitory effect of novel diallyldisulfide analogs on HMG-CoA reductase expression in hypercholesterolemic rats: CREB as a potential upstream target. *Life Sci* 2009;85:211–9.
- Slowing K, Ganado P, Sanz M, Ruiz E, Tejerina T. Study of garlic extracts and fractions on cholesterol plasma levels and vascular reactivity in cholesterol-fed rats. *J Nutr* 2001;131(Suppl):994S–9S.
- Lu Y, He Z, Shen X, Xu X, Fan J, Wu S, Zhang D. Cholesterol-lowering effect of allicin on hypercholesterolemic ICR mice. *Ox Med Cell Longev* 2012;48690:1–6.
- Gebhardt R. Inhibition of cholesterol biosynthesis by a water-soluble garlic extract in primary cultures of rat hepatocytes. *Arzneimittelforschung* 1991;41:800–4.
- Morihara N, Ide N, Weiss N. Aged garlic extract inhibits CD36 expression in human macrophages via modulation of the PPARgamma pathway. *Phytother Res* 2010;24:602–8.
- Morihara N, Ide N, Weiss N. Aged garlic extract inhibits homocysteine-induced scavenger receptor CD36 expression and oxidized low-density lipoprotein cholesterol uptake in human macrophages in vitro. *J Ethnopharmacol* 2011;134:711–6.
- Scharbert G, Kalb ML, Duris M, Marschalek C, Kozek-Langenecker SA. Garlic at dietary doses does not impair platelet function. *Anesth Analg* 2007;105(5):1214–8.
- Zhang XH, Lowe D, Giles P, Fell S, Connock MJ, Maslin DJ. Gender may affect the action of garlic oil on plasma cholesterol and glucose levels of normal subjects. *J Nutr* 2001;131:1471–8.
- Zhang XH, Lowe D, Giles P, Fell S, Board AR, Baughan JA, Connock MJ, Maslin DJ. A randomized trial of the effects of garlic oil upon coronary heart disease risk factors in trained male runners. *Blood Coagul Fibrinolysis* 2001;12(1):67–74.
- Kojuri J, Vosoughi AR, Akrami M. Effects of Anethum graveolens and garlic on lipid profile in hyperlipidemic patients. *Lipids Health Dis* 2007;6:5–10.
- Sobenin IA, Andrianova IV, Fomchenkov IV, Gorchakova TV, Orekhov AN. Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension. *Hypertens Res* 2009;32(6):433–7.
- Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. *Lipids Health Dis* 2010;9:119–25.
- Ried K, Frank OR, Stocks NP. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial. *Maturitas* 2010;67:144–50.
- Budoff MJ, Ahmadi N, Gul KM, Liu ST, Flores FR, Tiano J, Takasu J, Miller E, Tsimikas S. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. *Prev Med* 2009;49:101–7.

31. Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial. *Eur J Clin Nutr* 2013;67:64–70.
32. Steiner M, Li W. Aged garlic extract, a modulator of cardiovascular risk factors: a dose-finding study on the effects of AGE on platelet functions. *J Nutr* 2001;131(Suppl):980S–4S.
33. Zeb I, Ahmadi N, Nasir K, Kadakia J, Larijani VN, Flores F, Li D, Budoff MJ. Aged garlic extract and coenzyme Q10 have favorable effect on inflammatory markers and coronary atherosclerosis progression: a randomized clinical trial. *J Cardiovasc Dis Res* 2012;3(3):185–90.
34. Ahmadi N, Nabavi V, Hajsadeghi F, Zeb I, Flores F, Ebrahimi R, Budoff M. Aged garlic extract with supplement is associated with increase in brown adipose, decrease in white adipose tissue and predict lack of progression in coronary atherosclerosis. *Int J Cardiol* 2013;168:2310–4.
35. Larijani VN, Ahmadi N, Zeb I, Khan F, Flores F, Budoff M. Beneficial effects of aged garlic extract and coenzyme Q10 on vascular elasticity and endothelial function: the FAITH randomized clinical trial. *Nutrition* 2013;29:71–5.
36. Budoff M. Aged garlic extract retards progression of coronary artery calcification. *J Nutr* 2006;136(3, Suppl):741S–4S.
37. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. *Circulation* 2001;103:1194–7.
38. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;342:836–43.
39. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. *Arterioscler Thromb Vasc Biol* 1998;18:1386–92.
40. Allison GL, Lowe GM, Rahman K. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. *J Nutr* 2006;136(3, Suppl):789S–92S.
41. Qi R, Liao F, Inoue K, Yatomi Y, Sato K, Ozaki Y. Inhibition by diallyl trisulfide, a garlic component, of intracellular Ca(2+) mobilization without affecting inositol-1,4,5-trisphosphate (IP(3)) formation in activated platelets. *Biochem Pharmacol* 2000;60:1475–83.
42. Allison GL, Lowe GM, Rahman K. Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. *J Nutr* 2006;136(3, Suppl):782S–8S.
43. Allison GL, Lowe GM, Rahman K. Aged garlic extract inhibits platelet activation by increasing intracellular cAMP and reducing the interaction of GPIIb/IIIa receptor with fibrinogen. *Life Sci* 2012;91:1275–80.
44. Moriguchi N, Sumioka I, Moriguchi T, Uda N, Kyo E. Aged garlic extract enhances production of nitric oxide. *Life Sci* 2002;71:509–17.
45. Thomson M, Mustafa T, Ali M. Thromboxane(B2) levels in serum of rabbits receiving a single intravenous dose of aqueous extract of garlic and onion. *Prostaglandins Leukot Essent Fatty Acids* 2000;63:217–21.
46. Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. *J Agric Food Chem* 2005;53:6254–61.
47. Steiner M, Khan AH, Holbert D, Lin RI. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. *Am J Clin Nutr* 1996;64:866–70.
48. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. *BMC Cardiovasc Disord* 2008;8:13–25.
49. Ali M, Al-Qattan KK, Al-Enezi F, Khanafer RM, Mustafa T. Effect of allicin from garlic powder on serum lipids and blood pressure in rats fed with a high cholesterol diet. *Prostaglandins Leukot Essent Fatty Acids* 2000;62:253–9.
50. Harauma A, Moriguchi T. Aged garlic extract improves blood pressure in spontaneously hypertensive rats more safely than raw garlic. *J Nutr* 2006;136(3, Suppl):769S–73S.
51. Elkayam A, Peleg E, Grossman E, Shabtay Z, Sharabi Y. Effects of allicin on cardiovascular risk factors in spontaneously hypertensive rats. *Isr Med Assoc J* 2013;15:170–3.
52. Al-Qattan KK, Thomson M, Al-Mutawa'a S, Al-Hajeri D, Drobia H, Ali M. Nitric oxide mediates the blood-pressure lowering effect of garlic in the rat two-kidney, one-clip model of hypertension. *J Nutr* 2006;136(3, Suppl):774S–6S.
53. Mohamadi A, Jarrell ST, Shi SJ, Andrawis NS, Myers A, Cloutre D, Preuss HG. Effects of wild versus cultivated garlic on blood pressure and other parameters in hypertensive rats. *Heart Dis* 2000;2:3–9.
54. Sun X, Ku DD. Allicin in garlic protects against coronary endothelial dysfunction and right heart hypertrophy in pulmonary hypertensive rats. *Am J Physiol Heart Circ Physiol* 2006;291:H2431–8.
55. Das I, Khan NS, Sooranna SR. Nitric oxide synthase activation is a unique mechanism of garlic action. *Biochem Soc Trans* 1995;23:136S.
56. Weiss N, Papatheodorou L, Moriguchi N, Hilge R, Ide N. Aged garlic extract restores nitric oxide bioavailability in cultured human endothelial cells even under conditions of homocysteine elevation. *J Ethnopharmacol* 2013;145:162–7.
57. Tang G, Wu L, Liang W, Wang R. Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. *Mol Pharmacol* 2005;68:1757–64.
58. Rohner A, Ried K, Sobenin IA, Bucher HC, Nordmann AJ. A systematic review and metaanalysis on the effects of garlic preparations on blood pressure in individuals with hypertension. *Am J Hypertens* 2015;28:414–23.
59. Predmore BL, Kondo K, Bhushan S, Zlatopolsky MA, King AL, Aragon JP, Grinsfelder DB, Condit ME, Lefer DJ. The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. *Am J Physiol Heart Circ Physiol* 2012;302:H2410–8.
60. King AL, Polhemus DJ, Bhushan S, Otsuka H, Kondo K, Nicholson CK, Bradley JM, Islam KN, Calvert JW, Tao YX, et al. Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase-nitric oxide dependent. *Proc Natl Acad Sci USA* 2014;111:3182–7.
61. Chang SH, Liu CJ, Kuo CH, Chen H, Lin WY, Teng KY, Chang SW, Tsai CH, Tsai FJ, Huang CY, et al. Garlic oil alleviates MAPKs- and IL-6-mediated diabetes-related cardiac hypertrophy in STZ-induced DM rats. *Evid Based Complement Alternat Med* 2011;950150:1–11.
62. Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, Calvert JW. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. *Circ Heart Fail* 2013;6:1077–86.
63. Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Modis K, Panopoulos P, Asimakopoulou A, Gero D, Sharina I, Martin E, et al. Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. *Proc Natl Acad Sci USA* 2012;109:9161–6.
64. Altaany Z, Yang G, Wang R. Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. *J Cell Mol Med* 2013;17:879–88.
65. Zanardo RC, Brancialeone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. *FASEB J* 2006;20(12):2118–20.
66. Eto K, Kimura H. A novel enhancing mechanism for hydrogen sulfide-producing activity of cystathionine beta-synthase. *J Biol Chem* 2002;277:42680–5.
67. Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H2S in rat tissues. *Can J Physiol Pharmacol* 2003;81:848–53.
68. Wang YF, Mainali P, Tang CS, Shi L, Zhang CY, Yan H, Liu XQ, Du JB. Effects of nitric oxide and hydrogen sulfide on the relaxation of pulmonary arteries in rats. *Chin Med J (Engl)* 2008;121:420–3.
69. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem Biophys Res Commun* 1997;237:527–31.
70. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T, Zhu YC. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. *Cardiovasc Res* 2007;76:29–40.
71. Nie XM, Zhou YJ, Xie Y, Li YF, Yang Q, Zhou ZM. [Effects of stent coated with diallyl trisulfide on endothelial structure and function after coronary injury: experiment with dogs]. *Zhonghua Yi Xue Za Zhi* 2006;86:1125–8 (in Chinese).
72. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA Jr., Sessa WC. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. *J Biol Chem* 2003;278:44719–26.
73. Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, Jo H. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. *Am J Physiol Heart Circ Physiol* 2002;283:H1819–28.
74. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. *J Mol Cell Cardiol* 2007;42:271–9.
75. Lei YP, Liu CT, Sheen LY, Chen HW, Lii CK. Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein. *Mol Nutr Food Res* 2010;54(Suppl 1):S42–52.